December 1990
Kidney International;Dec1990, Vol. 38 Issue 6, p1230
Academic Journal
The article presents information on several abstracts of several papers presented in the 39th Scientific Meeting of the Dutch Society of Nephrology held in Maastricht, Netherlands on June 16, 1990. One of the papers "Angiotensin II (Ang II) Infusion Does Not Reverse the Antiproteinuric Effect of ACE Inhibition by Lisinopril in Man," by J.E. Heeg, P.E. de Jong, G.K. van der Hem and D. de Zeeuw, stated that angiotensin converting enzyme (ACE) inhibitors are known to lower urinary protein excretion in man with renal disease. This antiproteinuric effect has been attributed to the renal hemodynamic effects of ACE inhibition, presumably resulting in a fall in intraglomerular capillary pressure, due to the inhibition of systemic Ang II production.


Related Articles

  • THE JUNE 2003 BARRY M. BRENNER COMGAN LECTURE The future of renoprotection: Frustration and promises. Schieppati, Arrigo; Remuzzi, Giuseppe // Kidney International;Dec2003, Vol. 64 Issue 6, p1947 

    Considers the prospects for renoprotection, which involves the blockade of angiotensin II with an angiotensin-converting enzyme inhibitor in order to slow the progressive loss of renal function. Growth of the global burden of end-stage renal disease; Mechanisms of progression of renal disease;...

  • Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Klahr, Saulo; Morrissey, Jeremiah // Kidney International Supplement;Dec2002, Issue 82, p23 

    Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Angiotensin II (Ang II) regulates a number of genes associated with progression of renal disease. The regulation of gene expression by Ang II occurs through specific receptors that are...

  • Abstracts.  // Kidney International;Oct1992, Vol. 42 Issue 4, p1030 

    Discusses abstracts of papers presented at the 28th Meeting of the Australian and New Zealand Society of Nephrology in Melbourne, Victoria on February 26-28, 2005. "Low human kidney osmoprotectant levels are matched by low sodium and urea levels," by S. Chambers, P. Sizeland, M. Lever, L. Bason...

  • Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain. Hernández, Ángel Alonso; Moreso, Francesc; Bayés, Beatriz; Lauzurica, Ricardo; Sánz-Guajardo, Dámaso; Gómez-Huertas, Ernesto; Pereira, Porfirio; Paul, Javier; Crespo, Josep; Amenábar, Juan J.; Oliver, Juan; Serón, Daniel // NDT Plus;Jun2010 Supplement 2, Vol. 3 Issue suppl_2, pii21 

    Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established.

  • Is politics a part of ACEs' exclusion from studies?  // Drug Utilization Review;Dec2001, Vol. 17 Issue 12, p92 

    Reports on the issue on the exclusion of angiotensin-converting enzyme (ACE) inhibitors from the studies on the capability of angiotensin II receptor blockers to slow renal disease. Therapeutic use of ACE inhibitor in patients with Type 1 diabetes; Disadvantage of ACE inhibitors; Reason ACE...

  • Have we fallen off target with concerns surrounding dual RAAS blockade? Lattanzio, Michael R.; Weir, Matthew R. // Kidney International;Sep2010, Vol. 78 Issue 6, p539 

    A misinterpretation of the results from ONTARGET (Ongoing Telmisartan alone and in combination with ramipril Global Endpoint Trial) has sparked both efficacy and safety concerns within the nephrology community regarding the utilization of dual RAAS blockade to achieve more desirable renal...

  • Literature abstracts.  // Pediatric Nephrology;Dec2001, Vol. 16 Issue 12, p1044 

    Presents abstracts of studies related to nephrology. 'Collapsing Focal Segmental Glomerulosclerosis Following Treatment With High-Dose Pamidronate,' by G.S. Markowitz et al, published in the 2001 issue of the 'Journal of the American Society of Nephrology'; 'Compensatory Up-Regulation of...

  • ACE Inhibitors vs. ARBs for Patients with Diabetic Kidney Disease. Bailey, Justin // American Family Physician;7/1/2007, Vol. 76 Issue 1, p68 

    The article focuses on whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor blockers (ARBs) are better for all-cause mortality reduction and renal protection in patients with diabetic kidney disease. It compares the mortality benefit of ACE inhibitors or ARBs with...

  • Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Tarif, Nauman; Bakris, George L. // Kidney International Supplement;Dec1997, Issue 63, pS67 

    While the bulk of the existing data are in diabetic renal disease, there are some animal and clinical studies that compare the effects of angiotensin I (AT-1) receptor antagonists to angiotensin converting enzyme (ACE) inhibitors in renal disease of nondiabetic origin. Based on these data,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics